Lung Cancer News and Research

Latest Lung Cancer News and Research

Cedars-Sinai Phase I-II clinical trial may help combat recurrence of small cell lung cancer

Cedars-Sinai Phase I-II clinical trial may help combat recurrence of small cell lung cancer

AMP 2013: EKF Molecular Diagnostics to launch four new PointMan DNA enrichment kits

AMP 2013: EKF Molecular Diagnostics to launch four new PointMan DNA enrichment kits

immatics, Roche enter into cancer vaccine and immunotherapy deal

immatics, Roche enter into cancer vaccine and immunotherapy deal

Professor receives NOK 75M grant to develop idea for next generation personalized cancer therapy

Professor receives NOK 75M grant to develop idea for next generation personalized cancer therapy

Novel discovery of RUNX3 gene provides new insights on defence mechanism against lung cancer

Novel discovery of RUNX3 gene provides new insights on defence mechanism against lung cancer

Helsinn grants exclusive commercialization rights to Chugai Pharma Marketing for anamorelin drug

Helsinn grants exclusive commercialization rights to Chugai Pharma Marketing for anamorelin drug

Pneumococcal pneumonia linked to lung cancer risk

Pneumococcal pneumonia linked to lung cancer risk

Delmar Pharmaceuticals announces quarterly update, strengthens intellectual property portfolio

Delmar Pharmaceuticals announces quarterly update, strengthens intellectual property portfolio

Specialist lung cancer nurses could aid treatment

Specialist lung cancer nurses could aid treatment

CTCA doctor presents cutting-edge treatments for cancer patients to medical colleagues

CTCA doctor presents cutting-edge treatments for cancer patients to medical colleagues

Study suggests that therapies targeting KDM2A may benefit subset of NSCLS patients

Study suggests that therapies targeting KDM2A may benefit subset of NSCLS patients

Longer looks: Bad behavior treatment; end of life decisions

Longer looks: Bad behavior treatment; end of life decisions

ImmunoGen starts clinical testing with its EGFR-targeting ADC, IMGN289 for several types of cancers

ImmunoGen starts clinical testing with its EGFR-targeting ADC, IMGN289 for several types of cancers

Biothera announces top-line results from Phase 2b clinical trial in non-small cell lung cancer

Biothera announces top-line results from Phase 2b clinical trial in non-small cell lung cancer

Experimental drug effective in treating patients with non-small cell lung cancer

Experimental drug effective in treating patients with non-small cell lung cancer

FDG-PET parameter predicts locally advanced lung cancer survival

FDG-PET parameter predicts locally advanced lung cancer survival

DNA methylation signature marks recurrence in early stage lung cancer

DNA methylation signature marks recurrence in early stage lung cancer

Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy

Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy

Interim data from Phase 1B trial of an investigational anti-PD-1 immunotherapy in patients with previously-treated NSCLC announced by Merck

Interim data from Phase 1B trial of an investigational anti-PD-1 immunotherapy in patients with previously-treated NSCLC announced by Merck

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.